Deutsche Bank raised the firm’s price target on Apogee Therapeutics (APGE) to $118 from $108 and keeps a Buy rating on the shares. The firm says zumilokibart posted “credible” doses in atopic dermatitis, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics price target raised to $160 from $130 at Guggenheim
- Apogee Therapeutics price target raised to $125 from $95 at Citi
- Apogee Therapeutics price target raised to $130 from $89 at Canaccord
- Apogee Therapeutics: Strong Phase IIa IL‑13 Data Support Buy Rating and Long-Term Upside in Atopic Dermatitis
- APGE: Zumilokibart’s Best-in-Class Atopic Dermatitis Profile and Long-Acting Dosing Support Buy Rating and Re-Rating Potential